Edmond de Rothschild leads Genkyotex’s CHF18mm Series C round; adds on CHF25mm later
Executive Summary
Genkyotex SA (therapeutics for diseases caused by overproduction of oxygen radicals and superoxides) has completed a CHF18mm ($20.4mm) Series C financing. Edmond de Rothschild Investment Partners led and was joined by other new backers including Vesalius Biocapital Partners and MP Healthcare Venture Management, and existing shareholders Eclosion, the Specialized European Fund for Therapeutic Innovation (SEFTI; affiliated with Societe Generale Asset Management), and Fondation d’Aide aux Entreprises. EDRIP and Vesalius have contributed new board members, and executives from SEFT and MP Healthcare will be observers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice